福森药业(01652.HK)盐酸尼卡地平注射液一致性评价申请获批上市

阿斯达克财经
Dec 14, 2025

福森药业(01652.HK) 公布,全资附属河南福森研发的“盐酸尼卡地平注射液”一致性评价申请已获中国国家药品监督管理局批准,批准用于手术时异常高血压的紧急处置、高血压急症。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10